ArticleTheoretical medicine and bioethics2025
The ethics of anti-love drugs qua precommitment strategy.
Article in Theoretical medicine and bioethics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ethics of anti-love drugs - pharmaceutical interventions to dampen one's feelings of love for, say, a former partner - have been the subject of a growing body of research. Scientific research on these drugs is fairly nascent and ethical debates about their implications are therefore by necessity largely speculative. Nonetheless, insofar as future developments in anti-love drugs propose to affect a value as personal and important as love, these ethical debates are imperative. In this article, I propose to add a new dimension to ethical discourse on anti-love drugs by contextualising it within existing ethical debates on precommitment. An agent who consumes an anti-love drug does so to limit their future behavior - i.e. preventing themselves from reigniting their former relationship-based on their present preferences. The use of anti-love drugs is therefore an unambiguous example of a precommitment strategy. This recognition therefore allows one to draw on existing ethical research on precommitment to invigorate ethical discourse on anti-love drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.